AdvanDx, a maker of molecular diagnostics for infectious diseases, said today it has raised $8 million in new closing of its Series C round of financing, which first closed in 2007. The company, which has offices in Woburn, MA, and Vedbaek, Denmark, said the new funds came from two of its existing European investors, Scandinavian Life Science Venture and LD Pensions. AdvanDx plans to use the new funding for product development as well as global sales and marketing efforts.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
